Epidermolysis bullosa dystrophica

This phase 3 trial tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa, a rare disease that causes fragile skin and painful blisters. The therapy uses the patient's own skin cells, genetically corrected to produce collagen, and injects t…

This study tests a lab-made skin substitute on one patient with dystrophic epidermolysis bullosa, a rare disease causing fragile skin and chronic wounds. The goal is to see if the graft can reduce wound size and pain. It is an early-stage, single-patient trial, not a cure.

This study tests a treatment called D-Fi, made from a person's own skin cells that are genetically modified to produce a missing protein. It aims to see if injecting these cells into wounds helps them close completely compared to standard care alone. The trial includes 32 childre…

This trial tests a new approach for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. Researchers take a small piece of the patient's own skin, fix the faulty gene in a lab, grow it into a larger sheet, and graft it …

This study tests a stem cell treatment for epidermolysis bullosa, a rare disease causing fragile skin that blisters easily. About 91 people with two types of EB will receive the cells or a placebo through an IV. The main goal is to see if the treatment can safely close stubborn w…

This phase 3 trial tests whether ABCB5-positive stem cells given through an IV can safely and effectively heal wounds in people with epidermolysis bullosa, a rare genetic condition that causes fragile, blistering skin. The study includes 9 participants with a specific type of the…

This study is developing an artificial intelligence app to detect squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering condition. Twenty adults with RDEB and a history of skin cancer will submi…

This study tests whether a gel made from curcumin (the active part of turmeric) combined with blue LED light can heal painful mouth blisters in people with epidermolysis bullosa, a rare condition that makes skin and mucous membranes extremely fragile. Twenty participants will rec…

This early-stage study tests whether ELK-003 eye drops can safely reduce eye symptoms in people with two types of epidermolysis bullosa (EB), a rare condition causing fragile skin and blisters. About 20 participants will first be observed without treatment, then receive the eye d…

This study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…